Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Novo NordiskDanish pharma; GLP-1 originator (Ozempic 2017, Wegovy 2021). CagriSema (cagrilintide + semaglutide) FDA submission filed December 2025. Diabetes care leader; Novo Holdings acquired Catalent in 2024 to expand fill-finish capacity.
| Trial / Asset | Dose + Duration | Key Endpoint Result |
|---|---|---|
| CagriSema (cagrilintide + semaglutide) Phase 1b/2 | 2.4mg + 2.4mg weekly SC; 32 weeks | Phase 2 readout 2022 (in patients with type 2 diabetes): ~15.6% mean weight loss at 32 weeks at the combination dose vs ~5.1% semaglutide monotherapy + ~8.1% cagrilintide monotherapy at the same dose; supports the mechanistic synergy hypothesis (amylin + GLP-1 complementary satiety pathways) |
| REDEFINE-1 (Phase 3 obesity, registrational) | CagriSema 2.4mg + 2.4mg weekly SC; 68 weeks | Dec 2024 topline: 22.7% mean weight loss at 68 weeks vs 2.3% placebo (trial-product estimand; 20.4% vs 3.0% on the treatment-policy estimand), with 57.3% of CagriSema patients reaching the highest dose; statistically significant but below buy-side consensus of 25%+, causing ~20% NVO stock drop. Comparable to tirzepatide SURMOUNT-1 (~22% at 72 weeks) on absolute weight loss |
| REDEFINE-2 (Phase 3 obesity with type 2 diabetes) | CagriSema 2.4mg + 2.4mg weekly SC; 68 weeks | Mar 2025 topline: 15.7% mean weight loss at 68 weeks vs 3.1% placebo (primary endpoint was weight loss) in 1,206 adults with obesity or overweight and type 2 diabetes; HbA1c reduction (~1.9%) as a secondary endpoint |
| REDEFINE-3 (Phase 3 cardiovascular outcomes) | CagriSema; long-duration CVOT | Cardiovascular outcomes trial supporting CV-risk-reduction labeling claim, similar to semaglutide SUSTAIN-6 + SELECT trials; long-duration readout 2027-2028 |
| Amycretin Phase 1b oral (12 weeks) | Oral once-daily; multiple doses; 12 weeks | Mar 2024 topline: 13.1% total weight loss at 12 weeks at the high dose (placebo ~1.1%); among the strongest oral incretin readouts ever reported; positions amycretin oral against Rybelsus (oral semaglutide) + LLY orforglipron + GPCR aleniglipron + Pfizer (discontinued) + VKTX oral VK2735 |
| Amycretin Phase 1b/2a injectable (up to 36 weeks) | Subcutaneous weekly; multiple doses; up to 36 weeks | Jan 24, 2025 topline: weight loss of 9.7% (1.25mg, 20 weeks), 16.2% (5mg, 28 weeks), and up to 22.0% (20mg, 36 weeks) on the adherence estimand; 125-patient Phase 1b/2a; positions amycretin injectable as NVO's next-generation injectable beyond CagriSema |
| Amycretin Phase 2 oral (obesity) | Oral; dose-titration; topline 2025-2026 | Phase 2 program in obesity; larger cohort + extended duration; supports Phase 3 advancement decision; competitive readout vs orforglipron Phase 3 |
| Amycretin Phase 2 injectable (obesity) | Injectable; dose-titration; topline 2025-2026 | Phase 2 program in obesity for the injectable formulation; supports Phase 3 advancement decision |
| Mechanism distinction: amylin combination strategies | Combination vs single-molecule | CagriSema = two separate molecules (cagrilintide + semaglutide), each at its own dose. Amycretin = single molecule with dual GLP-1 + amylin receptor activity. The strategic difference: amycretin allows simpler dose-titration + manufacturing economics; CagriSema allows independent dose-adjustment of each component. NVO is pursuing both as a hedge |
| Editorial. Why these readouts matter | Strategic context | CagriSema's 22.7% Phase 3 result is a strong absolute number but the buy-side disappointment exposed how the market is pricing tirzepatide superiority. Amycretin's combination of strong Phase 1 efficacy + oral formulation potential gives NVO a credible long-term franchise extension beyond semaglutide. The collective question: do CagriSema + amycretin maintain GLP-1 #1/#2 leadership for NVO through 2030, or does the entire GLP-1 cycle eventually compress on tirzepatide + retatrutide superiority? |
2022-2027
Q1 2022-Q3 2025
2002-2025
$NVO
GLP-1 originator (Ozempic 2017, Wegovy 2021). Wegovy holds about 65% of US new prescriptions, though Lilly overtook Novo in share outside the US in early 2026. CagriSema (cagrilintide + semaglutide) FDA submission filed December 2025. Novo Holdings acquired Catalent for $16.5B in 2024 to expand fill-finish capacity from 2026.